Vivani Medical, Inc. (NASDAQ:VANI) Financings
Financings
| Raise | Date |
|---|---|
| Private placement of common stock Announced: about US$5.1M · US$1.01 a share Buyers: Gregg Williams; Aaron Mendelsohn Insiders: Purchased by Chairman Gregg Williams and director Aaron Mendelsohn Use of proceeds: Research and clinical development of NPM-139 semaglutide implant and other candidates, working capital and general corporate purposes | Nov 16, 2026 |
| Registered direct offering of shares of common stock Closed: US$1.48 a share · ThinkEquity Dealers: ThinkEquity (lead) Use of proceeds: Research and clinical development of product candidates, working capital and general corporate purposes | Jan 27, 2026 |
| Private placement of shares of common stock Closed: US$1.48 a share Buyers: Gregg Williams (1,351,351 shares of common stock at $1.48 per share) Insiders: All shares purchased by Gregg Williams, Chairman of the board Use of proceeds: Research and clinical development of product candidates, working capital and general corporate purposes | Jan 27, 2026 |
| Private placement of shares of common stock Announced: about US$10M · US$1.26 a share Buyers: entity beneficially owned by Gregg Williams Insiders: Two investors including an entity beneficially owned by Chairman Gregg Williams Use of proceeds: Secure financial position into second half of 2026 and accelerate development of NPM-139 into clinical-stage development | Aug 13, 2025 |
| Private placement of shares Update: about US$3M · US$1.03 a share | May 13, 2025 |
| Private placement of shares Announced: about US$8.25M · US$1.12 a share Buyers: Entity beneficially owned by Gregg Williams Insiders: The Company has entered into a securities purchase agreement with an entity beneficially owned by Gregg Williams, the Chairman of the board Use of proceeds: Extend cash runway into Q2 2026; accelerate development of NPM-139 semaglutide implant and continue development of NPM-115 | Mar 27, 2025 |